FrontlinePPS is our proprietary, first-in-class platelet protection technology for mitigating storage-related platelet deterioration, the so-called platelet storage lesion.
FrontlinePPS is designed to replace a portion of the plasma used to store platelets and is expected to modulate the cellular processes our scientists believe cause the changes in platelets which result in loss of viability and function. This should result in a higher dose of fully functional platelets at the point of transfusion.
Mediating the platelet storage lesion could reduce the number of platelet units transfused reducing patient risks and healthcare costs.
Platelets are the most expensive of blood components.
FrontlinePPS is expected to support extended platelet shelf life when used in conjunction with pathogen inactivation or point-of-issue bacterial tests.